Literature DB >> 1576767

Nephrocalcinosis.

N D Adams1, J C Rowe.   

Abstract

The pathogenesis of NC in VLBW infants appears to be multifactorial. The vulnerability of extreme immaturity and the underdevelopment of renal function may be the most important variables. In some ways, we view this problem as similar to that of retinopathy of prematurity. (Clearly the exposure of the retina to high partial pressures of oxygen contributes to the development of retinopathy of prematurity but other variables--some known, such as an immature retina, and others not yet defined--must be present.) Hypercalciuria is common in the VLBW infant, yet not all develop NC. Decreased glomerular filtration rate, low citrate excretion, and frequently an alkaline urine are in part due to the immaturity of renal function of these infants. The need for prolonged hyperalimentation resulting in increased oxalate excretion and the development of BPD frequently requiring diuretics that may cause phosphaturia and magnesium depletion and that may increase calcium excretion are more common in the smallest and sickest of premature infants. Even transient insults to the kidneys, such as hypoxia or hypotension or the use of nephrotoxic drugs that provoke tubular injury and cell death with the probability of crystal formation and growth by way of heterogeneous nucleation, are likely to occur more frequently in this vulnerable population.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1576767

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN: 0095-5108            Impact factor:   3.430


  10 in total

1.  Nephrocalcinosis in preterm babies.

Authors:  A Narendra; M P White; H A Rolton; Z I Alloub; G Wilkinson; J H McColl; J Beattie
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-11       Impact factor: 5.747

2.  An infant with hypercalcemia: answers.

Authors:  Stefano Guarino; Pierluigi Marzuillo; Andrea Apicella; Luigi Annicchiarico Petruzzelli; Angela La Manna
Journal:  Pediatr Nephrol       Date:  2013-10-19       Impact factor: 3.714

3.  Does citrate prevent nephrocalcinosis in preterm neonates?

Authors:  Eveline A Schell-Feith; Aukje Moerdijk; Paul H T van Zwieten; Harmine M Zonderland; Herma C Holscher; Joana Kist-van Holthe; Bert J van der Heijden
Journal:  Pediatr Nephrol       Date:  2006-10-13       Impact factor: 3.714

4.  Histological long-term outcome of furosemide-induced nephrocalcinosis in the young rat.

Authors:  U S Alon; R A Kaplan; L L Gratny; M A Nichols
Journal:  Pediatr Nephrol       Date:  1996-04       Impact factor: 3.714

Review 5.  Drug-Induced Urolithiasis in Pediatric Patients.

Authors:  Maria Chiara Sighinolfi; Ahmed Eissa; Luigi Bevilacqua; Ahmed Zoeir; Silvia Ciarlariello; Elena Morini; Stefano Puliatti; Viviana Durante; Pier Luca Ceccarelli; Salvatore Micali; Giampaolo Bianchi; Bernardo Rocco
Journal:  Paediatr Drugs       Date:  2019-10       Impact factor: 3.022

6.  Development of nephrocalcinosis in very low birth weight infants.

Authors:  Guido Hein; Detlef Richter; Friedrich Manz; Dieter Weitzel; Hermann Kalhoff
Journal:  Pediatr Nephrol       Date:  2004-03-31       Impact factor: 3.714

7.  Urinary NAG in children with urolithiasis, nephrocalcinosis, or risk of urolithiasis.

Authors:  Przemyslaw Sikora; Sara Glatz; Bodo B Beck; Ludwig Stapenhorst; Malgorzata Zajaczkowska; Albrecht Hesse; Bernd Hoppe
Journal:  Pediatr Nephrol       Date:  2003-08-13       Impact factor: 3.714

Review 8.  Hyperechoic kidneys in the newborn and young infant.

Authors:  T L Slovis; J Bernstein; A Gruskin
Journal:  Pediatr Nephrol       Date:  1993-06       Impact factor: 3.714

9.  Preterm neonates with nephrocalcinosis: natural course and renal function.

Authors:  Eveline A Schell-Feith; Joana E Kist-van Holthe; Paul H T van Zwieten; Harmine M Zonderland; Herma C Holscher; Dorine W Swinkels; Ronald Brand; Howard M Berger; Bert J van der Heijden
Journal:  Pediatr Nephrol       Date:  2003-10-02       Impact factor: 3.714

10.  Clinical pharmacology of furosemide in neonates: a review.

Authors:  Gian Maria Pacifici
Journal:  Pharmaceuticals (Basel)       Date:  2013-09-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.